Human Genome Sciences, Inc.

Development of gene-based protein and antibody drugs

Human Genome Sciences, Inc., is a pioneer in genomics for the discovery and development of new pharmaceutical products. The company is headquartered in Rockville, Maryland, and is listed on the NASDAQ National Market System under the ticker symbol HGSI.

H. Thomas Watkins, President and CEO
James H. Davis, PhD, Executive VP, General Counsel
Barry A. Labinger, Executive VP, Chief Commercial Officer
David C. Stump, M.D., Executive VP, Research and Development
Susan Bateson McKay, Senior VP, Human Resources
Timothy C. Barabe, Senior VP and CFO
Curran M. Simpson, Senior VP, Operations

Argeris N. Karabelas, Ph.D.

14200 Shady Grove Road
Rockville, MD 20850-3338
USA
Phone: +1-301-309-8504
Fax: +1-301-309-8512

Research and development is focused on novel protein and antibody drugs discovered through genomics-based research, and on new improved long-acting versions of existing drugs created using the company’s proprietary albumin fusion technology. Human Genome Sciences has nine products in clinical development, including drugs to treat diseases such as cancer, rheumatoid arthritis, lupus, hepatitis C, growth hormone deficiency, and immunodeficiencies.
The company holds over 400 patents; please refer to the company’s patent website for more information.

The company is conducting clinical trials for several products.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.